Using Probiotics to Reduce Hospital-Acquired Infections in Children Admitted to Intensive Care

Evaluation of Probiotics as an Adjunctive Therapy for the Prevention of Nosocomial Infections in Pediatric Intensive Care Unit : A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202601720379514

Enrollment

196

Registered

2026-01-23

Start date

2023-03-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Paediatrics

Interventions

Administration of Lactobacillus

Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All admitted patients to the PICU aged 1 month to 12 years

Exclusion criteria

Exclusion criteria: Patients will be excluded if they are surgical admissions; have suspected gastrointestinal perforation or obstruction; have severe neutropenia (= 0.5 × 10? cells/L); have chronic immunological diseases or have received immunosuppressive therapy within the three months prior to admission; are oncology patients receiving active treatment; are breastfed during the PICU stay; have received probiotic supplementation within the two weeks before admission; have absolute contraindications to enteral medication; have acute pancreatitis; or die within the first 72 hours of PICU admission.

Design outcomes

Primary

Measure	Time frame
Development of Hospital acquired infections	—

Secondary

Measure	Time frame
Length of PICU stay and mortality	—

Countries

Egypt

Contacts

Public ContactMarwan Mohamed Fahim Abdallah

Lecturer of Pediatrics Faculty of medicine Alexandria University

drmarwanfahim@gmail.com+201033961955

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026